Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)

Overview

NHS England has launched a 30 day consultation on Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages).

Haemophilia A is a rare condition that affects the blood's ability to clot. It is usually inherited and usually occurs in males. Emicizumab is a drug used to prevent bleeding or reduce the number of bleeds in people with haemophilia A. Emicizumab works by mimicking the action of factor VIII. Emicizumab binds to factor X (ten) and activated factor IX (nine) which brings those clotting factors near each other and activates the blood clotting system even if no factor VIII is present.

Related documents

• Policy proposition
• Evidence review
• Stakeholder engagement report
• Impact assessment report
• CPAG summary report
• Clinical panel report